Abstract:Phase I clinical trial based on toxicity probability intervals is a new class of dose-finding designs characterized by integrating the concept of intervals, instead of point estimates, in detection of the maximum tolerated dose. The purpose of this article is to explore and compare the performance of three novel designs including the two-parameter logistic regression model with categorized posterior probability design (LRcat), the modified toxicity probability interval design (mTPI) and the Bayesian optimal interval design (BOIN). A thorough numeric study with eight potential scenarios was conducted to examine critical operating characteristics. Robustness of the novel designs to the change in the target interval width and mis-specified priors was investigated in a sensitivity analysis following the simulation study. In addition, we also retrospectively analyzed a recent cancer phase I clinical trial to explore the performance of these designs in real-world application The results of our analysis showed that interval-based designs perform comparably to a traditional CRM design using posterior mean to define MTD in most scenarios. LRcat is more flexible than CRM and demonstrates robustness to the varying target toxicity interval. BOIN is safer than other designs and allocates less patients to overly-toxic levels. mTPI is more likely to allocate patients to suboptimal doses when the true MTD resides at the lowest/highest doses and performs poorly when the target interval is asymmetric. PUBLIC HEALTH SIGNIFICANCE Phase I cancer clinical trials are the indispensable step for the development of anticancer therapies. With the widespread application of phase I clinical trials, researchers and clinical investigators need up-to-date information about newly-developed phase I clinical trial methods. By providing the comparison result for a group of innovative phase I trial designs, our study facilitates choice of dose-finding method and leads to more efficient and ethical drug development to conquer cancer epidemic.

Utpi: A Utility‐based Toxicity Probability Interval Design for Phase I/II Dose‐finding Trials

A Utility‐based Bayesian Optimal Interval (U‐BOIN) Phase I/II Design to Identify the Optimal Biological Dose for Targeted and Immune Therapies

A90 a utility-based bayesian optimal interval (u-boin) phase i/ii design to identify the optimal biological dose for targeted and immune therapies

BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies.

Phase I–II Clinical Trial Design: a State-of-the-art Paradigm for Dose Finding

Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials

qTPI: A quasi-toxicity probability interval design for phase I trials with multiple-grade toxicities

TITE‐BOIN12: A Bayesian Phase I/II Trial Design to Find the Optimal Biological Dose with Late‐onset Toxicity and Efficacy

Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials

Gboin: a Unified Model-Assisted Phase I Trial Design Accounting for Toxicity Grades, and Binary or Continuous End Points

Probability Intervals of Toxicity and Efficacy Design for Dose-Finding Clinical Trials in Oncology.

PoD-TPI: Probability-of-Decision Toxicity Probability Interval Design to Accelerate Phase I Trials

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

MT-Keyboard: A Bayesian Model-assisted Interval Design to Account for Toxicity Grades and Types for Phase I Trials

Bayesian Optimal Interval Designs for Phase I Clinical Trials

A Bayesian Phase I/II Trial Design for Immunotherapy

Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.

Statistical Tutorial for Using Bayesian Optimal Interval (BOIN) Design for Phase I Single-Agent and Drug-Combination Trials

Comparison of novel phase I clinical trial designs based on toxicity probability intervals

A Dose-Finding Design for Phase I Clinical Trials Based on Bayesian Stochastic Approximation

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes